The value of the pharmaceutical market for pain relief in 2008 reflects this seeming worldwide epidemic of pain. The Global Pain Therapeutics Market assesses key pain management therapeutics - such as opioids, triptans, anticonvulsants, Cox-II inhibitors and traditional NSAIDs and are discussed in terms of their past, present and future value and the role they are playing in the effective management of pain. This report discusses the key products within each of these areas and outlines the drivers of these markets as well as the restraints on them.

The Global Pain Therapeutics Market also identifies and discusses trends and issues that will have a significant impact on the pain management market and profiles the leading companies in the field. The report provides the reader with valuable information and analysis regarding key products on the market and in clinical development.

This 438-page report includes 96 profiles of companies engaged in the development and/or commercialization of pain therapeutics and over 150 tables and graphs illustrating sales trends, past and present, as well as pipelines and demographic and market trends in the area of pain management.

Key features and highlights of this report:

• Extensive review of key products indicated for pain conditions and their market value and impact

• Discussion of the key drivers of and restraints on the global pain therapeutics market

• Qualitative analysis of key pain markets and products driving growth (opioids, NSAIDs, triptans, neuropathic pain therapies (anticonvulsants) and Cox-II inhibitors)

• Profiles and reviews of key pipeline products in development for fibromyalgia, cancer pain, post-operative pain, migraine pain, neuropathic pain and opioid therapies

• Profiles of nearly 100 companies engaged in the development and/or commercialization of pain therapeutics worldwide

• Overviews of treatment options for post-operative pain, migraine pain, cancer pain, fibromyalgia, arthritic pain, back pain, neuropathic pain, and the demographic impact of these conditions.

• Chapter devoted to the role of drug delivery technologies in the current and future treatment of pain

• Discussion of promising areas of research in a variety of pain areas and companies engaged in cutting edge research and development

Key questions answered in this report:

• What is the current state of the global pain therapeutics market?

• How has the Cox-II debacle effected the market for and treatment of pain conditions?

• What pain therapies, old and new, are today proving their market and clinical value?

• What new classes of pain therapeutics are in clinical development and which classes and therapies are demonstrating superior efficacy?

• Which diseases and conditions have the most room for growth in terms of unmet need and market demand?

1 METHODOLOGY AND EXECUTIVE SUMMARY
1.1 Report Objectives and Scope
1.2 Executive Summary

2 CAUSES, CLASSIFICATIONS AND GLOBAL IMPACT OF PAIN
2.1 Causes
2.1.1 Terminal Illness
2.1.2 Pain and Genetics
2.1.3 The Immune System and Pain
2.1.4 The Subjective Nature of Pain
2.1.5 Pain Transmission
2.1.5.1 Nociceptors
2.1.5.2 Pain Receptors
2.2 Classifications of Pain
2.2.1 Chronic Pain
2.2.2 Acute Pain
2.3 The Impact of Pain
2.3.1 Demographic Impact of Pain
2.3.2 Financial Cost of Pain

3 TREATING PAIN: DRUG CLASSES AND GUIDELINES
3.1 NSAIDs
3.2 Opioids
3.2.1 Chronic Pain and Opioids
3.3 Antidepressants
3.4 Anticonvulsants

4 POST-OPERATIVE PAIN OVERVIEW AND THERAPEUTICS OPTIONS
4.1 Impact of Post-operative Pain
4.2 Pain Intensity in Surgical Sites
4.3 Site-Specific Pain Relief
4.4 Post-operative Medications
4.4.1 Naropin
4.4.2 DepoDur, DepoMorphine and Propofol
4.4.3 Other Opioids for Pain Management
4.4.4 NSAIDs for Post-operative Pain

5 BACK PAIN OVERVIEW AND THERAPEUTIC OPTIONS
5.1 Sciatica
5.2 Facet Joint Problems
5.3 Osteoarthritis
5.4 Diseases and Back Pain
5.5 Low Back Pain
5.6 Pharmaceutical Relief for Back Pain
5.6.1 Transdermal Patches
5.6.2 Injections for Back Pain
5.6.3 Back Pain and Opioids
5.6.4 Tricyclic Antidepressants
5.6.5 Muscle Relaxers
5.6.6 Colchicine
5.6.7 Chronic Low Back Pain and Anticonvulsants

6 NEUROPATHIC PAIN OVERVIEW AND THERAPEUTIC OPTIONS
6.1 Nociceptive Versus Neuropathic Pain
6.2 Nociceptive and Neuropathic Mixed Pain
6.3 Neuropathic Pain Generation
6.4 Treating Neuropathic Pain
6.4.1 Tricyclic Antidepressants
6.4.2 Duloxetine
6.4.3 Transdermal Fentanyl
6.4.4 Tramadol
6.4.5 Ketamine and Alfentanil
6.4.6 Neurontin
6.4.7 Lyrica
6.4.8 Carbamazepine
6.4.9 Lidocaine

7 MIGRAINE OVERVIEW AND THERAPEUTIC OPTIONS
7.1 Impact of Migraines
7.2 Pharmacological Treatment of Migraine Pain
7.2.1 Fiorinal and Fioricet
7.2.2 Ergot Alkaloid Derivatives
7.2.3 Triptans
7.2.3.1 Comparing Triptans
7.2.3.2 Imitrex
7.2.3.3 Zomig
7.2.3.4 Maxalt
7.2.3.5 Relpax
7.2.4 Neuroleptics
7.2.5 Beta-Blockers
7.3 Alternative Therapies for Migraine

8 CANCER PAIN OVERVIEW AND THERAPEUTIC OPTIONS
8.1 Causes of Cancer Pain
8.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Cancer Pain
8.3 Opioids and Cancer Pain
8.3.1 Reluctance to Prescribe Opioids
8.4 Seizure Drugs for Cancer Pain

9 ARTHRITIC PAIN OVERVIEW AND THERAPEUTIC OPTIONS
9.1 Impact of Arthritis
9.2 Rheumatoid Arthritis
9.2.1 Causes
9.2.2 RA Demographics
9.2.3 Genetic Susceptibility
9.2.4 Environmental Factors
9.2.5 High Cost of Rheumatoid Arthritis
9.3 Osteoarthritis
9.3.1 Causes
9.3.2 Pharmacological Treatment of Osteoarthritis
9.3.2.1 Cox-2 Class
9.3.3 Pharmacological Treatment of Rheumatoid Arthritis
9.4 Antirheumatic Drug Classes
9.4.1 Nonsteroidal Anti-Inflammatory Drugs
9.4.2 Corticosteroids

10 FIBROMYALGIA OVERVIEW AND THERAPEUTIC OPTIONS
10.1 Manifestations
10.2 Impact of Fibromyalgia
10.3 Natural Treatments for Fibromyalgia
10.4 Prescription Treatments for Fibromyalgia
10.4.1 Treatment with Antidepressants
10.4.2 Muscle Relaxants
10.4.3 Sleep Modifiers
10.4.4 Anxiety Medications
10.4.5 Anticonvulsants
10.4.6 Antibiotics

11 NON-PHARMACEUTICAL PAIN TREATMENT
11.1 Acupuncture
11.1.1 Assessing Acupuncture’s Value
11.2 Osteopathic Manipulation
11.2.1 Osteopathic Treatment
11.2.2 Conditions Treated by Osteopaths
11.3 Physiotherapy
11.4 Reflexology
11.5 Neurostructural Integration Technique
11.6 Herbal Medicine
11.7 Neurolytic Block Injections
11.7.1 Examples of Neurolytic Blocks
11.8 Chemical Neurolytic Blocks
11.9 Cryoablation
11.1 Radiofrequency Lesioning
11.11 Neurosurgical Procedures
11.12 Chemical Ablation
11.13 Nerve Blocks
11.14 Neurostimulation and Pain Control
11.15 Electro Thermal Disc Decompression/ Intradiscal Electro Thermocoagulation
11.16 Selective Nerve Root Injections
11.17 Facet Joint Pain Block
11.18 Trigger Spot Injections
11.19 Peripheral Nerve Injections
11.2 Cervical and Lumbar Epidural Blocks
11.21 Cognitive Behavioral Treatment (CBT)

12 NSAID USE AND MARKET ANALYSIS
12.1 Overview
12.2 Over-the-Counter NSAIDs
12.2.1 Ibuprofen
12.2.2 Naproxen
12.2.3 Acetaminophen and Aspirin
12.3 Traditional Prescription NSAIDs
12.3.1 Diclofenac/Cataflam/Voltaren
12.3.2 Arthrotec
12.3.3 Mobic
12.3.3.1 Mobic’s Market Performance
12.3.3.2 Mobic Vs Other NSAIDs
12.3.4 DayPro
12.3.4.1 Rheumatoid Arthritis Relief from DayPro
12.3.4.2 Osteoarthritis Relief from DayPro
12.3.5 Relafen
12.3.5.1 Relafen Versus Naproxen and Aspirin
12.3.5.2 Endoscopy Trials
12.4 The Future of the NSAID Market
12.5 Drivers and Constraints of the NSAID Market

13 OPIOID USE AND MARKET TRENDS
13.1 Drawbacks of Opioid Therapy
13.2 Treating Chronic Pain
13.3 Key Opioid Products
13.3.1 Morphine
13.3.1.1 Increased Usage of Morphine
13.3.1.2 Cognitive and Psychomotor Effects
13.3.1.3 Extended Release Morphine
13.3.1.3.1 Kadian
13.3.1.3.1.1 Kadian and Naltrexone 188
13.3.1.3.1.2 Key Clinical Trial 188
13.3.2 Codeine
13.3.3 Oxycodone
13.3.4 Vicodin
13.3.5 Ultracet/Ultram
13.3.6 Duragesic
13.3.7 Fentora
13.3.8 Ionsys
13.4 Legal Regulation of Opioids
13.5 Side Effects
13.6 Adjuvant Medications
13.7 Opioid Market Analysis
13.7.1 OxyContin
13.7.1.1 Abuse-Resistant OxyContin
13.7.1.2 Generic Competition
13.7.2 Duragesic
13.7.3 Kadian
13.7.4 Ultracet/Ultram
13.7.5 Avinza
13.7.6 Actiq
13.8 The Future of the Opioid Market
13.9 Drivers and Constraints of the Opioid Market

14 TRIPTANS THERAPY MARKET
14.1 Overview
14.2 Leading Migraine Therapies
14.2.1 Imitrex/Imigran
14.2.2 Zomig
14.2.3 Relpax
14.2.4 Maxalt
14.2.5 Frova
14.3 Emerging Migraine Therapies
14.3.1 Migranal
14.3.2 Stavzor
14.4 Preventive vs. Abortive Therapy
14.5 The Future of the Triptans Market
14.6 Drivers and Constraints of the Triptan Therapy Market

15 ANTICONVULSANT MARKET
15.1 Overview
15.2 Leading Anticonvulsants
15.2.1 Lyrica
15.2.2 Neurontin
15.2.3 Topamax
15.2.4 Depakote
15.2.5 Lamictal
15.2.6 Trileptal
15.2.7 Tegretol
15.3 The Future of the Anticonvulsant Market
15.4 Drivers and Constraints of the Anticonvulsant Market

16 COX-2 INHIBITORS AND THE FUTURE
16.1 The Fall of Bextra
16.1.1 Post-Marketing Reports for Bextra
16.1.2 Withdrawal of Bextra
16.2 The Fall of Vioxx
16.2.1 Repercussions from the Vioxx Withdrawal
16.3 Celebrex: Surviving the Fallout
16.3.1 Black Box Warning
16.4 Cox-2 Pipeline Status
16.4.1 Prexige
16.4.1.1 TARGET Assessment
16.4.1.2 Future of Prexige
16.4.2 Arcoxia
16.4.3 Dynastat
16.5 The Future of the Cox-2 Class
16.6 Drivers and Constraints of the Cox-2 Market

17 PRODUCTS IN DEVELOPMENT
17.1 Key Opioid Products in Development
17.1.1 Sufentanil Patches
17.1.2 Chronogesic
17.1.3 Remoxy
17.1.4 Rapinyl
17.1.5 Hydromorphone Patches
17.1.6 M6G
17.2 Key Migraine Pain Therapies in Development
17.2.1 AZ-001
17.2.2 PRO-513
17.2.3 MK-0974
17.2.4 Botox
17.2.5 Trexima
17.2.6 NovaDel
17.2.7 Zogenix
17.3 Key Cancer Pain Therapies in Development
17.3.1 Rapinyl
17.3.2 Remoxy
17.3.3 Sativex
17.3.4 Ziconatide
17.3.5 Chronogesic Pain Therapy System
17.3.6 ASICs
17.3.7 Xen2174
17.4 Key Fibromyalgia Therapies in Development
17.4.1 Cymbalta
17.4.2 Pristiq (desvenlafaxine)
17.4.3 Milnacipran
17.4.4 Xyrem (sodium oxybate)
17.4.5 Other Fibromyalgia Research Areas
17.5 Key Post-operative Pain Therapies in Development
17.5.1 LidoPAIN SP
17.5.2 Dyloject
17.5.3 M6G
17.5.4 ROX-888
17.6 Key Neuropathic Pain Therapies in Development
17.6.1 Fentora
17.6.2 NGX-4010
17.6.3 NP-1
17.6.4 V3381
17.6.5 Cannabinor (CB2) IV
17.7 Cannabinoids
17.7.1 Sativex
17.7.2 Cannabinor (CB2) IV
17.8 Ion Channel Blockers
17.8.1 Ralfinamide
17.8.2 AZD9056
17.9 Vanilloid Receptors
17.9.1 REN-1654
17.9.2 AMG 517
17.9.3 SB-705498
17.1 Emerging Novel Drug Classes
17.11 Comparative Analysis of Emerging Therapies

18 THE ROLE OF DRUG DELIVERY IN EMERGING PAIN THERAPEUTICS
18.1 Delivery Options for Pain Therapeutics
18.2 Emerging Technologies for Delivery of Pain Therapeutics
18.2.1 Delivery Devices
18.2.2 More Convenient Administration Routes

19 PROMISING AREAS OF RESEARCH
19.1 Peptides
19.2 Epibatidine
19.3 Willow Bark
19.4 Chilli Peppers and Capsaicin
19.5 Cannabinoids
19.6 Receptors as Gateways
19.7 Chromaffin Cells
19.8 Homeopathic Remedies
19.9 Ion Channels
19.9.1 Calcium Channel Blockers
19.9.1.1 Case Study: Prialt
19.9.2 Sodium Channel Blockers
19.9.2.1 Tetrodotoxin
19.9.3 Vanilloid Receptors
19.9.4 Glutamate Receptor Antagonists
19.9.4.1 NMDA-Receptor Antagonists
19.1 NSRI Agents

20 COMPANY BRIEFS
20.1 Abbott Laboratories
20.2 Alexza Pharmaceuticals
20.3 Alpharma
20.4 Altea Therapeutics
20.5 Amgen
20.6 Anesiva (formerly AlgoRx Pharmaceuticals)
20.7 Aradigm
20.8 Argolyn Bioscience
20.9 AstraZeneca
20.1 Avigen
20.11 Bayer Schering
20.12 Baxter
20.13 Biogen Idec
20.14 Biovail
20.15 Boehringer Ingelheim
20.16 Bristol-Myers Squibb
20.17 Cadence Pharmaceuticals
20.18 CeNeS Pharmaceuticals
20.19 Cephalon
20.2 Cerimon Pharmaceuticals
20.21 Cipher Pharmaceuticals
20.22 CombinatoRx
20.23 Cypress Bioscience
20.24 Depomed
20.25 Durect Corporation
20.26 Eisai
20.27 Elan Pharmaceuticals
20.28 Eli Lilly
20.29 Elite Pharmaceuticals
20.3 Endo Pharmacuticals
20.31 Enhance Biotech (formerly Ardent Pharma)
20.32 EpiCept
20.33 Evotec Neurosciences
20.34 FemmePharma Global Healthcare
20.35 Forest Laboratories
20.36 GlaxoSmithKline
20.37 GW Pharmaceuticals
20.38 Horizon Therapeutics
20.39 Icagen
20.4 Indevus Pharmaceuticals
20.41 Innocoll Pharma
20.42 Ista Pharmaceuticals
20.43 Javelin Pharmaceuticals
20.44 Johnson & Johnson
20.45 Kalypsys
20.46 King Pharmaceuticals
20.47 Labopharm
20.48 Medtronic
20.49 Merck & Co
20.5 MGI Pharma
20.51 Nastech Pharmaceutical
20.52 NeuroCure
20.53 Neurocrine Biosciences
20.54 NeurogesX
20.55 Neuromed Pharmaceuticals
20.56 Neurorecovery
20.57 NovaDel
20.58 Novartis Pharmaceuticals
20.59 Noven
20.6 Nuvo Research
20.61 Organon
20.62 PainCeptor Pharma
20.63 Pain Therapeutics
20.64 Penwest
20.65 Pfizer
20.66 Pharmos
20.67 Phosphagenics
20.68 Pozen
20.69 ProEthic Pharmaceuticals
20.7 Purdue
20.71 Questcor Pharmaceuticals
20.72 Quigley Pharma
20.73 Renovis
20.74 Roche
20.75 RoxRo Pharma
20.76 Sanofi-Aventis
20.77 Sepracor
20.78 SkyePharma
20.79 Sosei
20.8 Symbollon
20.81 Tanabe Seiyaku
20.82 Targacept
20.83 TheraQuest Biosciences
20.84 TorreyPines Therapeutics
20.85 UCB Pharma
20.86 Vernalis
20.87 Vertex Pharmaceuticals
20.88 Victory Pharma
20.89 Wex Pharmaceuticals
20.9 Wyeth
20.91 Xenome
20.92 XenoPort
20.93 XTL Biopharmaceuticals
20.94 YM Biosciences
20.95 ZARS Pharma
20.96 Zogenix

TABLES AND GRAPHS
Table 1.1 Value of the Pain Market by Therapeutic Class 2006 ($ mn)
Graph 1.1 Pain Therapeutics Market Share by Class 2006
Table 1.2 Top 20 Pain Medications Worldwide in 2006 ($ mn)
Table 2.1 Characteristics and Treatment of Acute vs Chronic Pain
Graph 2.1 Top Causes of Pain
Table 2.2 Incidence of Pain Conditions in American Households
Table 3.1 Key Pain Management Drug Classes and Diseases/Conditions Treated
Table 3.2 NSAID Delivery Routes
Table 3.3 Traditional NSAIDs
Table 3.4 The Oxford League Table of Analgesic Efficacy
Table 3.5 Opioid Delivery Routes
Table 3.6 Well-Known Narcotic Analgesics
Table 3.7 Antidepressant Delivery Routes
Table 3.8 WHO Guidelines for Pain Therapy
Table 4.1 WFSA Analgesic Ladder
Table 6.1 Common Etiologies of Neuropathic Pain
Table 6.2 Drug Interactions of the Agents Used to Treat Neuropathic Pain
Graph 7.1 Difference in Prevalence of Migraine Headache among Men and Women by Age
Table 7.2 Popular Medicines for the Treatment of Migraines
Table 7.3 Preventive Headache Therapies
Table 7.4 Common Analgesics Prescribed for Mild Migraine Pain
Table 7.5 Ergot Alkaloid Derivatives for Migraine Pain
Table 7.6 NSAIDs and Cox-2 Inhibitors for Migraine Pain
Table 7.7 Triptans for Migraine Pain
Table 7.8 Patent Expirations for Leading Triptans
Table 8.1 Cancer Pain and Therapeutic Options
Table 8.2 Adjuvants to Opioids for Treating Cancer Pain
Table 8.3 Other Treatments for Cancer Pain
Table 8.4 Anticonvulsants for Cancer Pain
Graph 9.1 Percentage of Adults with Diabetes, Heart Disease, or High Blood Pressure Who Also Have Arthritis*
Table 9.1 Leading Causes of Years of Life Lost Due to a Disability for Both Sexes of All Ages
Table 9.2 Financial Impact of Employees Suffering RA
Table 10.1 Popular Treatments for Fibromyalgia
Table 11.1 Complementary and Alternative Medicine Use by US Adults (2002)
Table 11.2 Ten Most Common Complementary and Alternative Therapies (2002)
Table 11.3 Disease/Condition Most Frequently Treated with Complementary/Alternative Medicines
Table 12.1 Global Sales of Leading Prescription NSAIDs (Traditional) 2007
Table 12.2 Cox-2 NSAIDs
Table 12.3 Prescription and OTC Non-Selective NSAIDs
Graph 12.1 Prescription NSAID Product Market Share (Traditional vs Cox-2 Inhibitors) 2007
Graph 12.2 Prescription NSAID Product Market Share 2007
Table 12.4 Global Sales of Leading OTC NSAIDs 2007
Table 12.5 Sales of Advil* 2002-2008 ($ mn)
Graph 12.3 Sales of Advil 2002-2007
Table 12.6 Financial Forecast of Ibuprofen Sales 2007-2013 ($ mn)
Table 12.7 Sales of Aleve 2002-2008 ($ mn)
Graph 12.4 Sales of Aleve 2002-2007
Table 12.8 Sales of Aspirin* 2002-2008 ($ mn)
Graph 12.5 Sales of Aspirin 2002-2007
Table 12.9 Sales of Excedrin* 2002-2007 ($ mn)
Graph 12.6 Global Sales of Excedrin 2002-2007
Table 12.10 Sales of Voltaren 2003-2008 ($ mn)
Graph 12.7 Sales of Voltaren 2003-2007
Table 12.11 Financial Forecast of Voltaren Sales 2007-2013 ($ mn)
Table 12.12 Sales of Mobic 2003-2008 (€ mn)
Graph 12.8 Sales of Mobic 2003-2007
Table 12.13 Financial Forecast of Mobic Sales 2007-2013 ($ mn)
Table 12.14 Adverse Events (%) Occurring in ≥2% of Mobic Patients in a 12-Week Osteoarthritis Placebo and Active-Controlled Trial
Table 12.15 Financial Forecast of the NSAID Market 2007-2013 ($ mn)
Table 13.1 Overview of Opioid Analgesics
Table 13.2 Key Opioid Product Sales 2007
Graph 13.1 Global Market Share of Branded Opioid Products 2007
Table 13.3 Global Sales of OxyContin 2003-2008 ($ mn)
Graph 13.3 Global Sales of OxyContin 2003-2007
Table 13.4 Financial Forecast of OxyContin Sales 2007-2013 ($ mn)
Table 13.5 Percent of US Household Population 12 Years and Older Reporting Past Month Non-Medical Use of Psychotherapeutics
Table 13.6 Global Sales of Duragesic 2001-2008 ($ mn)
Graph 13.4 Global Sales of Duragesic 2001-2007
Table 13.7 Financial Forecast of Duragesic Sales 2007-2013 ($ mn)
Table 13.8 Global Sales of Kadian 2002-2008 ($ mn)
Graph 13.5 Global Sales of Kadian 2002-2007
Table 13.9 Global Sales of Ultracet/Ultram 2001-2008 ($ mn)
Graph 13.6 Global Sales of Ultracet/Ultram 2001-2007
Table 13.10 Global Sales of Avinza 2003-2008 ($ mn)
Graph 13.7 Global Sales of Avinza 2003-2007
Table 13.11 Global Sales of Actiq 2002-2008 ($ mn)
Graph 13.8 Global Sales of Actiq 2002-2007
Table 13.12 Financial Forecast of Cephalon’s Pain Franchise 2007-2013 ($ mn)
Table 13.13 Financial Forecast of the Global Opioid Market 2007-2013 ($ mn)
Graph 13.9 Financial Forecast of the Global Opioid Market 2007-2013
Table 14.1Sales of Triptan Drugs 2001-2008
Graph 14.1 Sales of Triptan Drugs 2001-2007
Table 14.2 Sales of Leading Migraine Therapies 2007
Graph 14.2 Leading Migraine Therapies, Market Share 2007
Graph 14.3 Geographic Market Share of Leading Triptan-Based Migraine Therapies 2007
Table 14.3 Sales of Imitrex/Imigran 2001-2008 ($ mn)
Graph 14.4 Sales of Imitrex/Imigran 2001-2007
Table 14.4 Financial Forecast of Imitrex/Imigran Sales 2007-2013 ($ mn)
Table 14.5 Sales of Zomig 2001-2008 ($ mn)
Graph 14.5 Sales of Zomig 2001-2007
Table 14.6 Financial Forecast of Zomig Sales 2007-2013 ($ mn)
Table 14.7 Sales of Relpax 2001-2008 ($ mn)
Graph 14.6 Sales of Relpax 2001-2007
Table 14.8 Sales of Maxalt 2001-2008 ($ mn)
Graph 14.7 Sales of Maxalt 2001-2007
Table 14.9 Sales of Frova 2005-2008 ($ mn)
Graph 14.8 Sales of Frova 2005-2007
Table 14.10 Financial Forecast of Triptans 2007-2013 ($ mn)
Table 15.1 Leading Anticonvulsants, Global Sales 2007
Graph 15.1 Leading Anticonvulsants, Market Share 2007
Table 15.2 Sales Growth in the Anticonvulsants Market 2001-2008 ($ mn)
Graph 15.2 Sales Growth in the Anticonvulsants Market 2001-2007 ($ mn)
Table 15.3 Leading Anticonvulsant Indications
Table 15.4 Sales of Lyrica 2004-2008 ($ mn)
Graph 15.3 Sales of Lyrica 2004-2007
Table 15.5 Financial Forecast of Lyrica Sales 2007-2013 ($ mn)
Table 15.6 Sales of Neurontin 2001-2008 ($ mn)
Graph 15.4 Sales of Neurontin 2001-2007
Table 15.7 Sales of Topamax 2001-2008 ($ mn)
Graph 15.5 Sales of Topamax 2001-2007
Table 15.8 Financial Forecast of Topamax Sales 2007-2013 ($ mn)
Table 15.9 Sales of Depakote 2001-2008 ($ mn)
Graph 15.6 Sales of Depakote 2001-2007
Table 15.10 Financial Forecast of Depakote Sales 2007-2013 ($ mn)
Table 15.11 Sales of Lamictal 2001-2008 ($ mn)
Graph 15.7 Sales of Lamictal 2001-2007
Table 15.12 Financial Forecast of Lamictal Sales 2007-2013 ($ mn)
Table 15.13 Sales of Trileptal 2001-2008 ($ mn)
Graph 15.8 Sales of Trileptal 2001-2007
Table 15.14 Sales of Tegretol 2001-2008 ($ mn)
Graph 15.9 Sales of Tegretol 2001-2007
Table 15.15 Financial Forecast of the Anticonvulsant Market 2007-2013 ($ mn)
Table 16.2 Sales of Celebrex 2003-2008 ($ mn)
Graph 16.1 Sales of Celebrex 2003-2007
Table 16.3 Sales of Arcoxia 2003-2008 ($ mn)
Graph 16.2 Sales of Arcoxia 2003-2007
Table 16.4 Post-Bextra Switching Trends
Table 16.5 Future Sales of Celebrex 2007-2013 ($mn)
Key Opioid Products in Development
Table 17.1 Migraine Drugs in Development
Table 17.2 Other Fibromyalgia Treatments in Development
Table 17.3 Promising Areas of Fibromyalgia Research
Table 17.4 Key Neuropathic Pain Therapies in Development
Table 17.5 Key Pipeline Products and Their Potential in Pain Management
Table 18.1 Most Common Delivery Routes for Pain Therapeutics
Table 20.1 Alexza’s Pain Therapeutics Pipeline
Table 20.2 Amgen’s Pain Therapeutics Pipeline
Table 20.3 Avigen’s Pain Therapeutic Pipeline
Table 20.4 Cadence’s Pain Therapeutics Pipeline
Table 20.5 CeNeS Pharmaceuticals’ Pain Therapeutics Pipeline
Table 20.6 Depomed’s Pain Therapeutics Pipeline
Table 20.7 Durect’s Pain Therapeutics Pipeline
Table 20.8 Eisai’s Pain Therapeutics Pipeline
Table 20.9 Elite’s Pain Therapeutics Portfolio
Table 20.10 Evotec’s Pain Therapeutics Pipeline
Table 20.11 Horizon’s Pain Therapeutics Pipeline
Table 20.12 Javelin Pharmaceuticals’ Pain Therapeutics Pipeline
Table 20.13 Kalypsys’ Pain Therapeutic Pipeline
Table 20.14 Pfizer’s Pain Therapeutics Pipeline
Table 20.15 Pozen’s Pain Therapeutics Pipeline
Table 20.16 Purdue Pharma’s Pain Therapeutics Portfolio
Table 20.17 Victory’s Pain Therapeutics Pipeline
Table 20.18 XenoPort’s Pain Therapeutics Pipeline